

**US Environmental Protection Agency
EPA Science Advisory Board
Homeland Security Advisory Committee (HSAC)**

**Consultation on the EPA's Emergency Consequence Assessment Tool (ECAT)
and
White Paper on the Microbial Risk Assessment (MRA) Framework**

**May 30, 2007
9:00 am - 6:00 pm Eastern Time
May 31, 2007
8:30 am - 12:00 noon Eastern Time
Woodies Building
1025 F Street, NW, Suite 3700
Washington, DC**

AGENDA

Wednesday, May 30, 2007

9:00 am	Convene the Consultation / Opening Remarks	Ms. Vivian Turner <i>Designated Federal Officer, SAB Staff Office</i>
	Welcome	Dr. Vanessa Vu <i>Director, SAB Staff Office</i> and Mr. Jonathan Herrmann <i>Director, NHSRC</i>
9:15 am	Review of Previous Work and Agency Response: Implications for Future Work. Scientifically Sound Risk Communication	Dr. Baruch Fischhoff, <i>Chair and Panel Members</i>
10:30	Break	
10:40 am	Review of the Agenda for the ECAT	Dr. Fischhoff, <i>Chair</i>
10:45 am	EPA's Remarks on the ECAT & Charge Questions	Dr. Kevin Garrahan <i>Technical Lead/NHSRC</i>
11:00 am	Committee's Response to the Charge I. Scope of the ECAT - Threat Agents - Threat Scenarios - Kinds of guidance provided II. Approach and Principles	Dr. Fischhoff and Committee

- III. Data Analysis, including Uncertainties
- IV. Usability of the ECAT, including User Guide
- V. Recommendations

12:00noon	Lunch	
1:00 pm	Resume Committee's Response	Dr. Fischhoff and Committee
5:15 pm	Public Comments Regarding the ECAT	
5:45 pm	Summary of Comments on the ECAT and Next Steps	Dr. Fischhoff, <i>Chair</i>
6:00 pm	Adjourn for the Day	Ms. Turner, <i>DFO</i>

Thursday, May 31, 2007

8:30 am	Convene the Consultation on the White Paper for the Microbial Risk Assessment (MRA) Framework	Ms. Vivian Turner, <i>DFO</i>
8:35 am	Review of Agenda for the White Paper for the MRA Framework	Dr. Baruch Fischhoff, <i>Chair</i>
8:40 am	EPA's Remarks on the White Paper for the MRA Framework & Charge Questions	Dr. Tonya Nichols <i>Technical Lead/NHSRC</i>
8:55 am	Committee's Response to the Charge I. Approach to Incident-Based MRA II. Pathogenicity Assessment for Decontamination III. Exposure Assessment for Decontamination IV. Uncertainties in MRA V. Usability of MRA	Dr. Fischhoff and Committee
11:30 am	Public Comments regarding the White Paper for the MRA Framework	
11:50 am	Summary of Recommendations and Next Steps	Dr. Fischhoff, <i>Chair</i>
12:00noon	Adjourn the Consultation	Ms. Turner, <i>DFO</i>